Press release
Scars Treatment Pipeline 2025: Innovation Driving Aesthetic and Clinical Advancements
Scars Treatment Pipeline
DelveInsight's "Scars - Pipeline Insight, 2025" offers an in-depth look into the evolving therapeutic pipeline aimed at improving scar treatment outcomes. Several pharmaceutical and biotech companies are advancing innovative therapies, targeting the biological mechanisms of scar formation such as fibroblast activity, collagen remodeling, and inflammatory pathways. Promising candidates in development include novel topical formulations, anti-fibrotic agents, monoclonal antibodies, RNA-based therapies, and regenerative medicine approaches, including stem cell and tissue engineering solutions.
The report comprehensively profiles pipeline products across various stages of clinical development, highlighting their mechanisms of action, delivery platforms, targeted scar types (hypertrophic, keloid, atrophic), and anticipated launch timelines. It also explores regulatory advancements, market drivers, and ongoing challenges such as variability in scar types, patient response, and long-term efficacy.
With increasing focus from researchers, pharmaceutical companies, and aesthetic medicine specialists, the scar treatment market is expected to witness significant advancements, paving the way for therapies that offer improved functional and cosmetic outcomes.
Interested in learning more about the current treatment landscape and the key drivers shaping the scars pipeline? Click here: https://www.delveinsight.com/report-store/scars-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Key Takeaways from the Scars Pipeline Report
• DelveInsight's scars pipeline analysis depicts a strong space with 8+ active players working to develop 10+ pipeline drugs for Scars treatment.
• The leading scars companies include Kringle Pharma, Innovo Therapeutics, CellinCells, CellionBioMed, Syntara, and others are evaluating their lead assets to improve the Scars treatment landscape.
• Key scars pipeline therapies in various stages of development include KP100, INV001, TRTP-101, CBM 401, SNT-5505, and others.
• In April 2025, AVAVATM announced that its advanced acne scar treatment using Focal Point TechnologyTM received clearance from the U.S. Food and Drug Administration (FDA). This clearance recognizes the platform's ability to treat acne scarring effectively using high energies, across all Fitzpatrick skin types (I-VI).
• In December 2024, AiViva Biopharma Inc., a clinical-stage biotechnology company, announced FDA clearance to test AIV001 (axitinib) via intradermal injection in facial skin. AIV001 is a pan-tyrosine kinase inhibitor in a proprietary formulation designed for prolonged drug release. The clearance was based on safety data from 67 subjects treated with AIV001 for BCC and scar management, showing non-facial skin tolerability and systemic exposure.
Request a sample and discover the recent breakthroughs happening in the scars pipeline landscape @ https://www.delveinsight.com/report-store/scars-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Scars Overview
Scars are the visible marks left on the skin following the healing of an injury, surgery, burn, acne, or inflammatory skin condition. They represent a natural part of the body's wound healing process, involving collagen remodeling and tissue repair. Depending on their size, type, and location, scars can range from barely noticeable to functionally or aesthetically debilitating.
There are several types of scars, including atrophic scars (such as acne scars), hypertrophic scars, keloids, and contracture scars. Each type has unique characteristics and treatment challenges. While some scars fade over time, others persist or worsen, leading to physical discomfort, restricted mobility, or psychosocial impact, especially when located in visible areas.
Currently, scar management includes topical therapies, laser treatments, corticosteroid injections, cryotherapy, surgical revisions, and silicone-based products. However, there remains a significant unmet need for targeted and effective treatments, especially for keloids and hypertrophic scars, which often recur after intervention.
With growing awareness of scar-related burden, the therapeutic landscape is expanding, focusing on novel anti-fibrotic agents, gene therapies, regenerative medicine, and biologic-based solutions aimed at modulating wound healing pathways. The field continues to witness robust clinical research and innovation, driven by both aesthetic concerns and the medical necessity of treating complex scars.
Find out more about scars medication @ https://www.delveinsight.com/report-store/scars-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Scars Treatment Analysis: Drug Profile
INV001: Innovo Therapeutics
INV001 is a topically applied small-molecule therapy being developed by Innovo Therapeutics for the prevention and treatment of hypertrophic scars and keloids. It targets HSP47, a key protein involved in collagen synthesis and secretion, which plays a crucial role in scar formation. By inhibiting HSP47, INV001 reduces excessive collagen production in fibroblasts without disrupting normal wound healing. Preclinical studies have shown positive outcomes in burn-induced scars in mini-pigs and incision-induced scars in rats. The drug is currently in Phase II clinical trials for scar treatment.
TRTP-101: CellinCells
TRTP-101 is a first-in-class stem cell-based therapy developed by Originator Cell and is currently in Phase I clinical development. This investigational treatment utilizes the regenerative capabilities of stem cells to repair or replace damaged tissue. Once delivered to the affected site, the stem cells differentiate into the required tissue types, aiding in functional and structural restoration. TRTP-101 is designed to promote natural tissue regeneration, reduce scarring, and improve healing outcomes in conditions involving tissue loss or significant scarring.
Learn more about the novel and emerging scars pipeline therapies @ https://www.delveinsight.com/report-store/scars-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Scars Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.
By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
By Route of Administration
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical
By Molecule Type
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy
Scope of the Scars Pipeline Report
• Coverage: Global
• Key Scars Companies: Kringle Pharma, Innovo Therapeutics, CellinCells, CellionBioMed, Syntara, and others.
• Key Scars Pipeline Therapies: KP100, INV001, TRTP-101, CBM 401, SNT-5505, and others.
Dive deep into rich insights for drugs used for scars treatment; visit @ https://www.delveinsight.com/report-store/scars-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Table of Contents
1. Introduction
2. Executive Summary
3. Scars Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Scars Pipeline Therapeutics
6. Scars Pipeline: Late-Stage Products (Phase III)
7. Scars Pipeline: Mid-Stage Products (Phase II)
8. Scars Pipeline: Early Stage Products (Phase I)
9. Therapeutic Assessment
10. Inactive Products
11. Company-University Collaborations (Licensing/Partnering) Analysis
12. Key Companies
13. Key Products
14. Unmet Needs
15. Market Drivers and Barriers
16. Future Perspectives and Conclusion
17. Analyst Views
18. Appendix
Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform, PharmDelve.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Scars Treatment Pipeline 2025: Innovation Driving Aesthetic and Clinical Advancements here
News-ID: 4041196 • Views: …
More Releases from DelveInsight
Alagille Syndrome Pipeline 2025: Targeted Innovations Shaping the Future of Rare …
The therapeutic landscape for Alagille Syndrome (ALGS)-a rare, genetic disorder primarily affecting the liver and bile ducts-is evolving rapidly, driven by increased research into its molecular underpinnings and unmet clinical needs. Characterized by bile duct paucity, cholestasis, cardiac abnormalities, and skeletal, ocular, and facial features, ALGS has historically been managed with symptomatic and supportive treatments. However, these approaches often fail to address the progressive liver damage and systemic complications associated…
Recurrent Blood Clots Market Expected to Witness Transformational Growth Through …
Recurrent Blood Clots, also called Thrombophilia, is a rare, life-threatening hematologic disorder characterized by complement-mediated hemolysis, thrombosis, and bone marrow failure. Despite being ultra-rare, PNH poses a high burden on patients due to chronic anemia, risk of fatal blood clots, and severe fatigue, making it a critical focus area for therapeutic innovation.
DelveInsight's latest report, "Recurrent Blood Clots - Market Insight, Epidemiology and Market Forecast - 2034," delivers comprehensive insights into…
Avascular Necrosis Market Set for Steady Growth Through 2034 | DelveInsight
Avascular Necrosis (AVN), also known as osteonecrosis, is a debilitating orthopedic disorder caused by the loss of blood supply to the bone, leading to bone tissue death and joint collapse. Commonly affecting the hip, AVN is often associated with trauma, long-term corticosteroid use, excessive alcohol intake, and underlying conditions such as lupus or sickle cell disease. Despite being relatively rare, AVN poses significant challenges due to delayed diagnosis, progressive pain,…
Atherosclerosis Market Expected to Expand Significantly Through 2034, Featuring …
Atherosclerosis, a chronic and progressive cardiovascular condition marked by the buildup of plaque within arterial walls, remains a leading cause of heart attacks, strokes, and peripheral vascular disease worldwide. Despite advances in lipid-lowering therapies and cardiovascular risk management, atherosclerosis continues to impose a substantial clinical and economic burden, especially in aging populations and individuals with comorbidities like diabetes and hypertension.
DelveInsight's latest report, "Atherosclerosis - Market Insight, Epidemiology and Market Forecast…
More Releases for Scars
Dermefface FX7 Review: A Solution For Scars?
Visit Official Website Here >> https://bit.ly/3B68KvF
Scars are reminders of the obstacles we have overcome; most wear them proudly. While this statement from Ashton Kutcher reads true to a few people, most of us would do without those reminders. Smooth, radiant skin is a point of pride for many people, and the 189.3 billion dollar skincare industry has proved this.
Unfortunately, scars are a part of life, and we can’t avoid them.…
Rising Awareness & Demand For Better Skin Propel Boxcar Scars Market Growth
Global Boxcar Scars Market: Market Outlook
Boxcar scars, a type of atrophic scars, are a problem, and a permanent one caused by acne vulgaris. Acne mainly affects 80 % of young people and 12 to 51 % of adults between the ages of 20 and 49. Acne scars can be emotionally and mentally distressful for patients.
To get in-depth information view the report
https://www.factmr.com/report/boxcar-scars-market
The Rise in Demand of Aesthetic Products: How a…
Hy Tape provides excellent protection to your healing scars.
You will fall in love with HY TAPE”
Scar tissue is thin and it requires extra attention and protection. When your skin is healing, it becomes more sensitive to the harmful effects of the sun’s ultraviolet rays. That is why it is crucial to take precautions and be more careful with your scar.
Having a wound and scar does not mean you can't go swimming, go outside for travel, or do anything…
Dermatological Burns, Scars and Ulcers Market 2018 Stage Development, Drug Targe …
This report provides an overview of the pipeline landscape for dermatological burns, scars and ulcers. It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for pressure ulcers, venous leg ulcers, burns and scars, and features dormant and discontinued products.
Click here to know more about Dermatological Burns, Scars and Ulcers Market Pipeline research report @
https://www.reportsnreports.com/contacts/requestsample.aspx?name=1715918
A pressure ulcer is an injury that breaks down…
“Invisible Scars” by Peter Sykes is published
ISBN #978-1787195516
“Invisible Scars” by Peter Sykes is published
Will Paul and Kate’s marriage survive the stresses of their hospital work and their past traumas?
About the Book:
Whilst Paul and Kate work alongside each other as doctor and nurse on the surgical ward, strains in their relationship emerge. And when Kate's baby dies and Paul's inexperience costs lives, doubt and despair hang in the air and their marriage appears to be doomed.
However, in…
Combination Treatments for Scars Market Trends and Opportunities by 2017 – 202 …
Scar treatment is a technique that is utilized to limit the scars marks so that it seem more consistent with the skin tone and surface surrounding. Scars are marks that stay after a wound recovers and unavoidable aftereffects of damage or surgery. Scars are of different types, which includes keloid scars, contracture scars, hypertrophic scars and acne scars. Combination therapeutics are one of the most adopted treatment option for different…
